AirSculpt Technologies, Inc. (AIRS)
NASDAQ: AIRS · Real-Time Price · USD
0.7636
-0.0734 (-8.77%)
Nov 16, 2026, 3:35 PM EST - Market open
← View all transcripts

A.G.P. Virtual Consumer Showcase

Nov 11, 2026

Summary

Same-center sales and balance-sheet measures improved during the transformation, but Q3 weakened amid search changes and uneven center execution. GLP-1 procedures are scaling, with operational fixes underway and de novo growth no earlier than Q4 2027.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

—maybe from liposuction, and the market opportunity there.

Yogi Jashnani
CEO, AirSculpt Technologies

Absolutely, Aaron. For those who don't know us, AirSculpt is a premier body contouring provider. We do fat removal, fat transfer, skin tightening, and we do these services at 31 centers across 20 states and Canada. All our procedures are done by board-certified plastic surgeons or cosmetic surgeons. Our patented method mainly removes unwanted fat and tightens skin in a minimally invasive procedure. Our patients are awake throughout the procedure. It's done under local anesthesia. The result is a premium, consistent patient experience, which is centered around the outcome. Many of our patients are back to their normal routines within 24-48 hours. What really sets it apart from traditional liposuction is just the efficiency in which you remove the fat while preserving it for fat transfers, while creating shorter recovery because you're using local anesthesia.

You then pair that with skin tightening, which today, 80%+ of our cases get skin tightening along with fat removal. We've scaled our process to over $150 million in revenue, and what's really interesting is we are one of the few providers who's uniquely positioned to benefit from the GLP-1 transformation. As more people lose weight, everybody's trying to sell GLP-1s. We are one of the few who can address the side effects, namely loose skin, stubborn fat deposits, because GLP-1 is not that targeted, and loss of volume. You hear terms like Ozempic face, which are growing. Our services, and we've expanded our services to address loose skin, stubborn fat deposits, as well as loss of volume. We see that as a $100+ million long-term revenue opportunity, just from those procedures in our existing centers alone.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay, great. Thanks for the overview, Yogi. You guys reported last Friday, but bigger picture over the past 18 months or two years, the business has gone through a meaningful reset. The same-store sales had been improving meaningfully. They were flat in the first half of 2026. 3Q took a little bit of a step back, where same-store center revenues were down about 7.5%. You talked about how transformations aren't always linear, so maybe kind of give you this opportunity to kind of walk through what's been fixed, what drove the 3Q setback, and why you feel like you're still on the right part of that transformation today.

Yogi Jashnani
CEO, AirSculpt Technologies

Absolutely. I joined early 2025, and over the last seven odd quarters, we have made meaningful progress on revenue, costs, and our balance sheet. Let me address those. Same-center sales, we have made about a 19-point improvement compared to a year ago. We did that through a number of things, including just sharpening our sales and marketing, new procedures that are coming in, and just tighter execution in our clinics to support and deliver for our patients. Secondly, we've expanded our gross margin to about 60%, and then there's a lot more cost activity which we've already done and additionally doing, which will start to pay off in 2027. Thirdly, we've cut our debt by about half and just completed the refinancing of our debt, extending the maturity of our term loan to 2031. The transformation is definitely starting to yield results.

As with any transformation, not a linear process, Aaron, as you said. Q3 was a step back. Couple of reasons for that. One was just what's going on with how consumers shop, and the second was some performance challenges at our existing locations. I can give you a little bit more detail on that. On the consumer journey side, look, our average ticket is $12,000-$13,000. It is a considered purchase. The journey involves a decent amount of research, and much of that research starts with Google. What has changed now is Google now answers the questions themselves, rather than the consumers coming through to us. Many consumers still come through to us, but enough of them get their responses from Google and often never click onto our site or any provider site. That meant organic traffic from Google was down year-over-year.

The good thing is demand we are still seeing is relatively steady. The consumer journey is changing, and we are evolving our methods to follow the consumer along that journey. We're starting to see that we're making gains in October and now in November in how our lead patterns are recovering. They're not where we need to be, but we're startingly starting to see improvements this quarter compared to what we saw in Q3. That is one bucket, and then the second bucket is just performance of our centers. There were a handful of centers where our whether it was marketing, sales, or just execution in center was not up to par to what we would expect. Again, all of those are well within our control, and we're working urgently to address those and get those centers back to parity.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Mm-hmm. Yeah, maybe on that last part, just within those couple of centers that you called out on the call and again today, what are some of the maybe the actions that you're taking, and how are you applying best practices to those centers and maybe even applicable across all centers so that they can all be performing optimally?

Yogi Jashnani
CEO, AirSculpt Technologies

Absolutely. As you can imagine, in a multi-unit scenario, there are centers which are underperforming, there are centers which are performing really well. When we look at our successful centers, what they do consistently is they have marketing, sales, and operations working in unison and firing on all cylinders. In our lower-performing centers, one of those areas is currently challenged. Specifics vary by location, but it's within those three areas. Our actions are targeted, so marketing changes for particular locations that need it, and those are faster, so we're starting to see traction over there already. We strengthened our sales leadership, so we just brought in a regional sales leader for one of our critical regions who's going to uplift the entire region, frankly. Then we're upgrading talent where needed.

We're also taking what's working in our strongest centers, and whether that's in the sales process, in the conversion funnel, in what's working in marketing, and rolling it out across our network. From a timing perspective, the actions are well underway, so we expect that by season, which is usually spring for us, that we are ready and have all of this behind us.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay, great. Thanks for that, Yogi. You alluded to it in your opening, but GLP-1 procedures, you talked about the market opportunity. You've said that's a $100 million long-term opportunity. You now rolled that out across centers. How's that rollout now that it's largely complete, and how are you thinking about marketing those offerings to consumers?

Yogi Jashnani
CEO, AirSculpt Technologies

Yeah. Aaron, just on GLP-1s, look, we continue to be excited about the potential over there. Just as a recap, as GLP-1s took off in 2023, we started to see, particularly in early 2025 as I joined, that the conversations we were having with prospective patients was changing. We're seeing a lot of patients come in with, "Yeah, I've been on GLP-1s, now I got side effects after 12, 18 months, which I need addressing." That was really a trigger, just listening to the consumer, what was happening in our consultation room every single day, and expanded our procedures to address loose skin further. We already have a tremendous solution for fat removal, fat transfer, and some skin tightening. The last year or so, we've been first piloted, and over the last six months, really, it's been in rollout. Six months or less, it's been in rollout.

We've gone from low single-digit penetration in terms of percentage of cases on GLP-1-related procedures to it's now about 10% of our volume. What we're also learning is the patient who is looking for a fat removal solution, their research, their patterns, what support they need is different than someone who is now facing a side effect and needs more education, more nurture. Even though the procedures are well within our wheelhouse, we are adapting our sales and marketing engine to really scale it up. It also includes how we speak to these patients. We're bringing on a new marketing agency that will help with consumer messaging and how to go to market and expanding our GLP-1 opportunity.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay. No, really appreciate that. Maybe just briefly talk about the economics and how they compare to your core fat removal. So different in terms of ticket size, gross margin.

Michael Arthur
CFO, AirSculpt Technologies

Yeah, I can take that, Aaron. Yeah, so skin tightening, skin removal, they have a gross margin profile like our core business, so around 60% is kind of the gross margin for our overall business. Just standalone skin removal has a slightly lower ticket than our core procedures, but many of our patients, we usually find many of our patients are combining it with fat removal and/or fat transfer as well as skin tightening and skin removal. So the overall ticket usually is in line with our average kind of sales price. So, year-to-date, for example, through Q3, ASP has stayed basically roughly flat at $12,800 or so. We don't really expect it to materially impact either gross margins positively or negatively, and/or ticket price.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay, great. Thanks. We talked about some of the specific center issues that impacted Q3. Let's go back to the first thing you mentioned with the Google AI Overviews. You talked about that being a big headwind in the quarter as well. Leads were down, pushed your CAC up to about $3,800 from $3,100 a year ago. Talk about and give us more color maybe on how you're adapting your marketing changes to adjust to the new world of AI search.

Yogi Jashnani
CEO, AirSculpt Technologies

Yeah. Absolutely. As we mentioned, look at a $12,000-$13,000 ticket, we are a considered purchase. A lot of that consideration happens through research, through Google, and as that journey is being interrupted with Google itself answering the questions, which by the way, they're using our website to answer those questions. For us, the consumer gets the information anyways, never clicks through to our site. It impacted us just enough to show up in the numbers. The demand is still present, so what we're doing is, how do we capture that demand and how do we address that demand? Three main things. One is, how do we get cited more often in AI search? Our citation work is running on schedule. We are starting to see traction over there.

We are starting to see that the leading indicators of how often, whether it's Google AI or broadly the LLMs are citing us, that percentage is going up. Early days, but we're encouraged by what we're seeing. The second is diversifying our sources of leads as well. That research doesn't just happen on Google. There is also word of mouth, there's referral, there's offline engagement for patients. We're building out our local marketing capabilities. We will continue to invest in our brand so people associate us with not just fat removal, but also addressing side effects of GLP-1 and an overall body contouring platform. The demand is still there, one, where people are still searching, how do we show up more often through getting cited in AI search? Second, outside of search, outside of digital channels, how do we show up in local and build our brand?

Thirdly, anybody who we are engaging with, conversion rate has held steady through Q3. Anybody who fills out a lead form, they've been converting. How do we continue to keep that conversion rate stable and enhance it? Oddly enough, AI tools allow us to do that. They allow us to address patient needs in a far more targeted manner, support our sales team in a far more targeted manner so they can meet our patients' needs, and improve conversion rate hopefully in the coming quarters.

That's really been our plan.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Taking that to the P&L, you talked about scaling back some of your brand spend in the recent quarter you announced last Friday. Maybe talk about how you're thinking about brand investment and balancing that with near-term profitability.

Michael Arthur
CFO, AirSculpt Technologies

Yeah, I can jump in here, Aaron. Yeah, so brand marketing is still important to us long term, and frankly, probably more important now in the world of AI Overviews. So, it almost kind of reinforces what we talked about in Q2 of the decision to do that, to drive brand, kind of top of the funnel brand marketing, brand awareness, direct kind of organic leads to our website. We definitely believe in that long term. However, as lead generation's kind of been under pressure due to the AI Overview disruption, we thought it was prudent to moderate that incremental brand marketing spend to preserve profitability and make sure we're redirecting, short-term redirecting those dollars towards initiatives that support the near-term lead generation that Yogi's been talking about.

But long term, we still believe it's really an important part of our marketing strategy to invest and lean into the brand marketing portion of it. Short term, obviously going to moderate it as we navigate kind of this disruptive period.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Mm-hmm. Maybe talk about some organic ways as kind of bringing in new customers. You guys are hosting your first ever open house that you guys announced last call. It's coming up. Maybe talk about the open house that you'll be having across all the centers, what it is, what's the goal of the event, and how these could become a regular part of the business to attract new customers.

Yogi Jashnani
CEO, AirSculpt Technologies

Yeah. I'm really excited about this one. First of all, what it is, it's all day long tomorrow, November 12th. We literally open up our clinics for prospective patients to visit, meet our surgeons, learn more about our services, but not just our services, general trends in aesthetics related to body contouring. It's a very different way for us to engage with consumers. We are also partnering with local businesses to drive reciprocal traffic to each other. Throughout the day, we would have patients coming in, both physical talks as well as virtual presentations.

Over time, it's one of the ways in which we build offline marketing and offline engagement to both meet the needs of the patient who might need more information, but also might not be ready to pull the trigger, but wants to make sure that they understand the setting, the environment in which we are operating. It is not always about fill out a lead form, convert, and get the surgery. It's also in the consideration process, how do we become a trusted partner? Ultimately, it creates an additional pipeline of engaged consumers who can turn into patients. This is our first one. We're really eager to see what the engagement is, just what the attendance is, and the content we get from that, how do we propagate that further to further educate our patients, learn from it, and adapt.

I expect the events like these would become more regular and also generating partnerships in our local communities and building further inroads over there

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

All right, great. If anyone is near a center, then go check it out tomorrow and learn. Let us talk about some of the overall consumer. You alluded to it a couple times, right? It's a high average price, average around just under $13,000. Can you walk us through the state of the consumer? You alluded to some softness in that being in the quarter, and financing options available, how you're leaning into promotion and new offerings that should help the consumer and make it more accessible.

Yogi Jashnani
CEO, AirSculpt Technologies

For sure, Aaron. Just a few things, so let me address them. From a consumer perspective, we still see the consumer environment remains choppy for consumer discretionary purchases. That's been the case for a while. I don't think that's lost on anyone, and many other companies have reported that as well. What we are encouraged by is the overall demand for aesthetics still continues to be there. We're seeing underlying trend changes, as I said, with GLP-1s, the kind of procedures that address GLP-1 side effects are growing double digits, for example. But overall, the consumer remains in a soft spot. We get it. We are continuing to execute on our transformation, and we've gotten the improvements on revenue trajectory, costs and a balance sheet regardless of that.

What we are seeing is that financing is a big part of our business, so about half of our consumers finance their procedures. Many of them take 12-month no-interest loans. So it's for more cash flow management, rather than, "Hey, I cannot afford the procedure." We do see financing has a positive impact on conversion on the margins. That's been relatively stable. As it relates to promotional activity, we do regular promotions, just to make sure we have a fresher message for consumers. But as you can see from our average selling price, that's not impacted price point. Our main focus on promotional activities is to ensure the consumer sees the value that we're driving, and they are seeing that.

As a result, ASP has been essentially flat year-to-date through Q3, and roughly has been, as you mentioned, towards in a tight range, like 12.5-13 for an extended period of time now. We do see the consumer is challenged. We are executing despite that. When the consumer turns, that becomes an added tailwind for us, but we're not waiting for that to happen.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Absolutely. Right, and even as we look to 2027, one of the new key themes for consumers, kind of the K-shaped economy, right? You guys obviously have, I would imagine, a higher income consumer, the K-shaped economy. Your expectations for the consumer in 2027, do you feel like your business is well-positioned given where the consumer has been going despite there being some softness?

Yogi Jashnani
CEO, AirSculpt Technologies

Absolutely. We are not counting on the macro environment to improve for next year. We're focused on what can we do on more effective marketing to drive lead generation, how do we convert better on sales productivity, and then really how do we expand our new procedures, like scaling up GLP-1 procedures. Again, slightly different consumer mindset, so we have to crack the code on that. If the consumer sentiment improves, that is an upside for us. All of the challenges we talked about in our Q3 earnings, we're working hard to make sure we're ready for season, if not sooner, with solutions so that we are really able to capitalize when consumers start to engage as well. As a quick reminder, Q3, Q4 tends to be our seasonal low. I think first half months are roughly 30% larger than second half months in terms of revenue.

Definitely trying to get ready for starting spring timeframe, how do we make sure that we've overcome some of the challenges, and then go from there.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay, great. Let us talk about centers. You have 31 centers today. You said refinancing provides more flexibility for future de novo expansion, though it seems like right now you're focused more on just improving the same-store sales. Let us talk about store expansion, how big of a priority that is for you, and what needs to happen before we get to a state of de novo growth?

Yogi Jashnani
CEO, AirSculpt Technologies

Yep, absolutely. Maybe I can get started, and Michael, would love to get your inputs as well. Historically, we've done really well on de novo openings. We used to open about five or so at our peak, and those have good paybacks. Michael can speak to the financials over there. We purposely took a pause on de novo openings in 2025, 2026. We said there are two markers we need to see to get back into de novos. One is same-store sales stabilization, and then the second is just refinancing and debt. The refinancing is done on same-store sales. We want to see some continued stabilization. Obviously, Q3 was a setback. That is where our focus is. We still see de novos as a long-term growth vector. There is more than 100 that we can go into just in the U.S. alone.

We're not in San Francisco, we're not in Oakland, we're not in Portland, we're not in Indy, we're not in Long Island. I can keep going down large population centers where we see opportunity. When we are ready, we would announce those. We have started the pre-planning. That includes, what are the 5-10 target cities we'd go after? What would be the clinic size? We do a smaller footprint where we can still serve patient needs. How we do them, frankly, faster, so that coming out of the gate, historically it's taken us about 12 months or longer. How do we reduce that time a bit? Even then, at the earliest, we would have Q4 2027 as our first opening. Right now, priority remains existing centers.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay, great. Then maybe, Michael, can you talk about the new store economics and payback, and how big of a white space opportunity you see over the long term?

Michael Arthur
CFO, AirSculpt Technologies

Yeah, sure. Maybe I'll start with just a brief kind of overview on the unit economics on a mature center. So, a mature, of our 31 clinics, basically we average $4 million-$5 million of revenue per center, and all of them are all profitable and have significant contribution margins to the business. That's kind of why we're bullish, and that means they're profitable and they work. The model works in New York City as well as Salt Lake City or Kansas City. That just creates, as we talk about white space, the opportunity is pretty large there. We're not kind of only restricted to large metro areas. We have opportunity to expand in mid-market, small market, large market opportunities. But $4 million-$5 million is the average revenue. They're all really profitable and contribute significantly to profitability for the business.

A new center, as Yogi alluded to, historically has been $1 million-$2 million of upfront CapEx, and is usually profitable within six months and paying back within a year, certainly within two, which for any multi-site consumer business that I've at least seen, those are really attractive economics. That's what has us excited about it and can create a lot of value for all shareholders when we turn it on. We think we can do it more economically and faster once we get it kind of up and running. Again, as Yogi alluded to on the white space, we have 31 clinics. We've done research and looked at markets. Studies would tell us we could easily open up 200 centers before we see any real saturation in those markets by opening up that incremental clinic.

There is a lot of runway ahead of us before we get to that point. As Yogi mentioned, when we were doing de novos, we were averaging four or five de novos a year. I hope we'll certainly get back to that run rate, but with a more efficient model in many cases, we're hoping we could do more and capture that demand over time.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay, great. Thanks. I'm going to combine this profitability question. As we do think about profitability of the business, gross margins, it's fluctuated a bit, generally in the low 60s, and then taking that down to EBITDA. You did take down your guidance a bit to 9%-10% from 12%-14%. Understanding you have not given 2027 guidance yet, just thinking about the long-term opportunities, how should we think about what is an optimal margin profile for AirSculpt?

Michael Arthur
CFO, AirSculpt Technologies

I will start with gross margin since it is what you led to when I talked about EBITDA. Gross margin in Q3 was 60%, and that, as I mentioned, has been historically where the business has seen gross margin consistently, given really how the business model is set up. Cost of services is largely variable between our surgeon costs, nursing costs, medical supplies. All that is relatively variable and moves up and down with revenue. That is why we can consistently deliver around that 60% gross margin. There are lease costs in there that is fixed. That's maybe about 5% of revenues, it's a small portion of overall cost of services. 60% I think still on a gross margin perspective is where we would see it.

There's opportunity on the edges to expand, but we're talking basis points or percentage points here, not going from 60% to 70% on gross margin. On EBITDA, we continue to balance investing into the growth initiatives, into marketing and de novos with profitability. We have been instituting stronger cost disciplines and operating efficiencies to make sure that while we grow, we grow profitably, and at some level, profitability outpaces top-line growth. We have been doing that. We've been after the cost savings for the last two years. It hasn't yet borne out in EBITDA, but we certainly feel confident the combination of enhanced sales and marketing efforts, de novo plans, and that cost discipline, that will start to really show through in 2027. We would expect strong results.

We obviously haven't given 2027 guidance yet, but I think you can tell from me and Yogi's tone that we're excited about the opportunity here at AirSculpt. While Q3 was a little bit of a blip in the transformation, we think we're headed on the right path, and we're excited about 2027.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Okay, fantastic. All right, we're going to take this one question before we close things out. You talked about the GLP-1 related procedures, went from low single digits to 10% of cases. Just real quickly, are you seeing that as incremental volume in patients, or are you seeing some cannibalization from patients switching from core fat removal to some of the GLP-1 related procedures?

Yogi Jashnani
CEO, AirSculpt Technologies

Yeah. Aaron, for us, what we see is these are patients who are, in the main, coming in and getting both procedures done. As folks come in for GLP-1 related procedures, they come in for loose skin, so they are incremental, but they end up also getting, in many cases, fat removal done or skin tightening done. So it's been really good. It's actually expanded the opportunity for us and brings in new customers who might not have considered us historically.

Aaron Grey
Managing Director of Equity Research, Alliance Global Partners

Fantastic. All right. Again, Yogi, Michael, thank you so much. Again, that is AirSculpt Technologies, traded on the NASDAQ, ticker AIRS. Yogi, Michael, thanks so much for joining me, and thank you everybody for tuning in.

Michael Arthur
CFO, AirSculpt Technologies

Thanks for having us.